Statement Of Changes In Equity [Abstract]

Hyloris Pharmaceuticals SA - Filing #3166135

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity
39,069 EUR
80,761 EUR
476,000 EUR
121,513 EUR
140,000 EUR
4,460 EUR
2,162 EUR
53,909 EUR
1,136 EUR
140,000 EUR
121,513 EUR
476,000 EUR
476,000 EUR
1,622 EUR
1,136 EUR
4,460 EUR
4,460 EUR
121,513 EUR
1,622 EUR
64,246 EUR
140,000 EUR
65,381 EUR
55,045 EUR
54,805 EUR
476,000 EUR
48,056 EUR
3,827 EUR
103,693 EUR
2,391 EUR
129,000 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)
15,380 EUR
11,906 EUR
Other comprehensive income
- EUR
- EUR
Comprehensive income
15,380 EUR
15,380 EUR
11,906 EUR
10,770 EUR
10,770 EUR
Issue of equity
5,000 EUR
- EUR
14,366 EUR
634,000 EUR
14,995 EUR
Increase (decrease) through share-based payment transactions, equity
540,000 EUR
540,000 EUR
560,000 EUR
560,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.